Cyberonics' poker-chip-size device, surgically implanted in the chest, is approved for treating drug-resistant epilepsy and has moved into final-stage human tests for the far bigger market of drug-resistant depression.
On October 13th a study published in Science Translational Medicine revealed that early-stage trials show a new tuberculosis vaccine may work against drug-resistant strains of that killer disease.